Hyperpolypharmacy is a predictor of mortality after left ventricular assist device (LVAD) implantation

Hyperpolypharmacy is a predictor of mortality after left ventricular assist device (LVAD) implantation

Background: The prevalence of (hyper)polypharmacy in patients on left ventricular assist device (LVAD) support and its effect on clinical outcomeis unknown. Therefore, we aimed to determine the prevalence of (hyper)polypharmacy in LVAD patients and evaluate its association with mortality and complic...

Full description

Bibliographic Details
Main Authors: Lauren Dautzenberg, Lieke Numan, Wilma Knol, Monica Gianoli, Manon G. van der Meer, Anne-Marie Troost-Oppelaar, Aline F. Westendorp, Marielle H. Emmelot-Vonk, Linda W. van Laake, Huiberdina L. Koek
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:American Heart Journal Plus
Subjects:
LVAD
MCS
Hyperpolyfarmacy
Polypharmacy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666602222001501

Internet

http://www.sciencedirect.com/science/article/pii/S2666602222001501

Similar Items